• Oragenics posted a GAAP net loss of USD 2.53 million, widening 11.3% year over year.
• Operating loss widened to USD 2.59 million as total operating expenses climbed 51.24% to USD 2.59 million.
• R&D spend more than doubled to USD 1.18 million, driven by higher external regulatory and clinical consulting for ONP-002.
• G&A expense rose 11.97% to USD 1.42 million, reflecting about USD 405,000 in higher patent-related costs.
• Cash and cash equivalents totaled USD 3.9 million at June 30, 2026; ONP-002 Phase IIa in Australia enrolled 9 participants with no serious adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037749), on August 13, 2026, and is solely responsible for the information contained therein.